A little more than a year ago Sanofi $SNY handed ImmunoGen a $30 million payment to gain exclusive development rights to a slate of experimental cancer drugs in the pipeline, including the Phase II drug SAR566658, an ADC targeting CA6 spotlighted in the deal that was in development for triple negative breast cancer.
Today, it’s history.
The French pharma giant wrote the drug off, saying that it was ending development efforts for the that drug as well as a TB vaccine program.
We’ don’t know why it failed to make the cut — just that it isn’t in the pipeline anymore. I’ve asked for an explanation, which I’ll pass along if it comes along.
Sanofi had another bleak quarter to report today, with falling sales figures for their diabetes operations as well as vaccines, where the company has been pummeled by a number of factors — including the dangers highlighted around their one-time blockbuster jab Dengvaxia.
The one big success was seen at their Genzyme unit in Boston, as rare diseases continue to be immune from the market forces that are shriveling sales in other units. Nobody talks about it any more, but the Genzyme buyout was engineered by ex-CEO Chris Viehbacher as he was trying to restructure the Paris-based company.
Sanofi has also continued to enjoy pipeline successes for its drugs developed with Regeneron, but internally there’s still little about R&D that is worth boasting about, with the possible exception of isatuximab. The company recently bought out Ablynx as well as Bioverativ in an effort to shake off the downward trajectory.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,300+ biopharma pros who read Endpoints News by email every day.Free Subscription